Literature DB >> 31908770

"Anagrelide-induced pulmonary arterial hypertension": a rare case of drug-induced pulmonary arterial hypertension.

Keiko Sumimoto1, Yu Taniguchi1, Yoichiro Matsuoka1, Hiroyuki Onishi1, Noriaki Emoto1, Ken-Ichi Hirata1.   

Abstract

Pulmonary arterial hypertension can be associated with exposure to certain drugs or toxins. However, only a few cases of drug-induced pulmonary arterial hypertension have been previously reported. Anagrelide is an oral imidazoquinazoline agent that is prescribed for reducing elevated platelet counts in patients with myeloproliferative disorders. We report the case of a 70-year-old female patient who developed pulmonary arterial hypertension after taking anagrelide for the treatment of polycythemia vera. Pulmonary arterial hypertension promptly improved after the discontinuation of anagrelide. Anagrelide-induced pulmonary arterial hypertension is a very rare disease, and our case shows that it might be reversible.
© The Author(s) 2019.

Entities:  

Keywords:  anagrelide; drug-induced pulmonary arterial hypertension; polycythemia vera

Year:  2019        PMID: 31908770      PMCID: PMC6935878          DOI: 10.1177/2045894019896682

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  8 in total

1.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Authors:  Christophe Guignabert; Carole Phan; Andrei Seferian; Alice Huertas; Ly Tu; Raphaël Thuillet; Caroline Sattler; Morane Le Hiress; Yuichi Tamura; Etienne-Marie Jutant; Marie-Camille Chaumais; Stéphane Bouchet; Benjamin Manéglier; Mathieu Molimard; Philippe Rousselot; Olivier Sitbon; Gérald Simonneau; David Montani; Marc Humbert
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

2.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

Review 3.  Drug-induced pulmonary arterial hypertension: a review.

Authors:  Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 4.  Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.

Authors:  M Humbert
Journal:  Eur Respir Rev       Date:  2010-03

5.  Pulmonary arterial hypertension in patients treated by dasatinib.

Authors:  David Montani; Emmanuel Bergot; Sven Günther; Laurent Savale; Anne Bergeron; Arnaud Bourdin; Helene Bouvaist; Matthieu Canuet; Christophe Pison; Margareth Macro; Patrice Poubeau; Barbara Girerd; Delphine Natali; Christophe Guignabert; Frédéric Perros; Dermot S O'Callaghan; Xavier Jaïs; Pascale Tubert-Bitter; Gérard Zalcman; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Circulation       Date:  2012-03-26       Impact factor: 29.690

6.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

7.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997

8.  Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Authors:  Gunnar Birgegård; Carlos Besses; Martin Griesshammer; Luigi Gugliotta; Claire N Harrison; Mohamed Hamdani; Jingyang Wu; Heinrich Achenbach; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

  8 in total
  1 in total

1.  Anagrelide-Induced Supraventricular Tachycardia: A Case Report.

Authors:  Faraz Badar; Hayder Azeez; Zeinab Abdulrahman; Aqsa Ashraf; Asma Iftikhar
Journal:  Cureus       Date:  2022-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.